Get notified when TWST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Securities Litigation (worsened) — Securities class action reached a $17.1M settlement in principle, up from preliminary stage.
NASDAQ: TWST Twist Bioscience Corp 10-Q

Twist Bioscience revenue up 23.2% to $118.4M, but operating loss widens and cash drops 42%

Filed August 3, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 4, 2025 · ~1 min read

Key Changes

  • high

    Revenue grew 23.2% to $118.4M, driven by DNA synthesis, protein solutions, and NGS applications.

    MD&A: Revenue verify on EDGAR →
  • high

    Cash and equivalents fell $84M to $117.4M, reflecting continued losses and investments.

    MD&A: Liquidity verify on EDGAR →
  • medium

    New $200M at-the-market equity program established; no shares sold yet.

    MD&A: ATM Program verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.

Partner

Trade TWST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify